v3.10.0.1
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2018
Dec. 31, 2017
Current assets    
Cash and cash equivalents $ 118,440 $ 12,821
Accounts receivable 62,694 60,427
Inventories 6,829 7,474
Other current assets 6,307 5,153
Total current assets 194,270 85,875
Property and equipment (net of accumulated depreciation of $49,492 and $40,530, respectively) 41,004 36,504
Intangible assets, net 69,909 74,165
Goodwill 147,019 147,019
Other assets 2,937 891
Total assets 455,139 344,454
Current liabilities    
Accounts payable 9,200 10,450
Accrued compensation 15,187 9,482
Accrued expenses and other liabilities 7,517 6,144
Short-term portion of capital leases and car loans 6,675 5,239
Short-term portion of loans 7,217 3,750
Pharma contract liability 1,259 1,406
Total current liabilities 47,055 36,471
Long-term liabilities    
Long-term portion of capital leases and car loans 6,663 5,303
Long-term portion of loans, net 89,764 66,616
Revolving credit facility, net 0 24,516
Long-term pharma contract liability 1,199 283
Deferred income tax liability, net 6,899 6,688
Total long-term liabilities 104,525 103,406
Total liabilities 151,580 139,877
Commitments and contingencies - see Note I
Redeemable convertible preferred stock    
Series A Redeemable Convertible Preferred Stock, $0.001 par value, (50,000,000 shares authorized; 0 and 6,864,000 shares issued and outstanding) 0 32,615
Stockholders' equity    
Common stock, $0.001 par value, (250,000,000 shares authorized; 92,980,783 and 80,462,574 shares issued and outstanding, respectively) 93 80
Additional paid-in capital 354,487 230,030
Accumulated other comprehensive income 536 274
Accumulated deficit (51,557) (58,422)
Total stockholders’ equity 303,559 171,962
Total Liabilities and Stockholders' Equity $ 455,139 $ 344,454

Source